title: The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
abstract: With the use of a cisplatin-based chemotherapy, metastatic testicular cancer has become a model for a highly curable malignant disease. Current data show that 70% to 80% of patients with this disease will achieve long-term survival following cisplatin/etoposide/bleomycin therapy. The role of high-dose chemotherapy with autologous stem cell support is being investigated in metastatic germ cell cancer in attempts to improve outcome for patients whose disease relapses after standard-dose chemotherapy and for those who present initially with advanced metastatic disease. Prognostic categories for patients receiving high-dose salvage chemotherapy have recently been developed: cisplatin-refractory disease, beta-human chorionic gonadotropin values greater than 1,000 U/L, and primary mediastinal germ cell tumors are factors characterizing patients who will derive less benefit from high-dose chemotherapy than those with chemosensitive disease at relapse. While standard-dose salvage chemotherapy achieves only a 20% long-term survival rate, high-dose salvage chemotherapy may yield a cure rate of approximately 40%. A randomized study comparing high-dose therapy with conventional-dose therapy (IT94 coordinated by the European Group for Blood and Marrow Transplantation) in patients with relapsed disease is ongoing to substantiate this observation. The use of dose-intensive therapy as first-line treatment is currently being studied by several institutions. High-dose therapy may be better tolerated when used first line compared with its use in the salvage situation, and may also achieve a rapid initial cell kill before cytostatic drug resistance develops. The German Testicular Cancer Study Group has developed a sequential high-dose combination regimen of cisplatin/etoposide/ifosfamide given with granulocyte colony-stimulating factor and peripheral blood stem cell support for four cycles every 3 weeks. This ongoing study, started in 1990, had accrued 218 patients with advanced testicular germ cell tumors as of June 1997. Of 141 evaluable patients receiving dose levels 1 through 5, 82 (58%) have achieved complete remission with no evidence of disease and 32 (23%) have achieved partial remission with marker normalization. The early death rate was 8%. Overall and event-free survival rates at 2 years are 78% and 73%, respectively, with a projected 5-year overall survival rate of 74%. Despite favorable preliminary results, this approach cannot be considered standard treatment. Currently, high-dose chemotherapy with peripheral blood stem cell transplantation should be administered to patients with testicular cancer only within controlled clinical trials to allow long-term cure rates and treatment-related late side effects to be evaluated.
authors.affiliation: Medizinische Klinik und Poliklinik, Eberhard-Karls-Universitaet Tuebingen, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Bokemeyer
authors.forename: A
authors.initials: A
authors.lastname: Harstrick
authors.forename: J
authors.initials: J
authors.lastname: Beyer
authors.forename: B
authors.initials: B
authors.lastname: Metzner
authors.forename: U
authors.initials: U
authors.lastname: Rüther
authors.forename: J T
authors.initials: JT
authors.lastname: Hartmann
authors.forename: K
authors.initials: K
authors.lastname: Holstein
authors.forename: H G
authors.initials: HG
authors.lastname: Derigs
authors.forename: R
authors.initials: R
authors.lastname: de Wit
authors.forename: J
authors.initials: J
authors.lastname: Casper
authors.forename: P
authors.initials: P
authors.lastname: Schöffski
authors.forename: I
authors.initials: I
authors.lastname: Kührer
authors.forename: H J
authors.initials: HJ
authors.lastname: Illiger
authors.forename: B
authors.initials: B
authors.lastname: Kempf
authors.forename: A
authors.initials: A
authors.lastname: Reichle
authors.forename: A
authors.initials: A
authors.lastname: Föller
authors.forename: D K
authors.initials: DK
authors.lastname: Hossfeld
authors.forename: J T
authors.initials: JT
authors.lastname: Fischer
authors.forename: W E
authors.initials: WE
authors.lastname: Berdel
authors.forename: H H
authors.initials: HH
authors.lastname: Gerhartz
authors.forename: H
authors.initials: H
authors.lastname: Kirchner
authors.forename: K H
authors.initials: KH
authors.lastname: Pflüger
authors.forename: H
authors.initials: H
authors.lastname: Ostermann
authors.forename: L
authors.initials: L
authors.lastname: Kanz
authors.forename: H J
authors.initials: HJ
authors.lastname: Schmoll
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018237:Germinoma / Q000188:drug therapy* / Q000556:secondary* / Q000628:therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D011379:Prognosis; D016879:Salvage Therapy; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000628:therapy
chemical_list: D016179:Granulocyte Colony-Stimulating Factor